Table 3.

Clinical developmental stages of topical JAKinibs for skin diseases

Disease	JAKi	Target	Route	Phase of development	Trial identifier
Alopecia areata	Ruxolitinib	JAK1/JAK2	Topical	Phase II	NCT02553330
	Tofacitinib	JAK1/JAK3	Topical	Phase II	NCT02812342
	Ifidancitinib	JAK1/JAK3	Topical	Phase II	NCT03759340
Atopic dermatitis	Ruxolitinib	JAK1/JAK2	Topical	Phase III	NCT03745651
			Topical	Phase III	NCT03745638
			Topical	Phase I (paediatric)	NCT03257644
			Topical	Phase I	NCT03920852
	Delgocitinib	Pan-JAK	Topical	Phase II	NCT03725722
			Topical	Phase I	NCT03826901
	Tofacitinib	JAK1/JAK3	Topical	Phase II	NCT02001181
	Brepocitinib	JAK1/TYK2	Topical	Phase II	NCT03903822
	Ifidancitinib	JAK1/JAK3	Topical	Phase II	NCT03585296
Chronic hand eczema	Delgocitinib	Pan-JAK	Topical	Phase III	NCT04871711
			Topical	Phase III	NCT05355818
			Topical	Phase II	NCT02664805
Cutaneous GVHD	Ruxolitinib	JAK1/JAK2	Topical	Phase II	NCT03395340
			Topical	Phase II	NCT03954236
Discoid lupus erythematosus	Delgocitinib	Pan-JAK	Topical	Phase II	NCT03958955
Healthy	PF-06263726	Pan-JAK	Topical	Phase I	NCT01981681
Hidradenitis suppurativa	Ruxolitinib	JAK1/JAK2	Topical	Phase II	NCT04414514
Lichen planus	Ruxolitinib	JAK1/JAK2	Topical	Phase II	NCT03697460
Necrobiosis lipoidica	Ruxolitinib	JAK1/JAK2	Topical	Phase II	NCT04492618
Psoriasis	Ruxolitinib	JAK1/JAK2	Topical	Phase II	NCT00820950
			Topical	Phase II	NCT00617994
			Topical	Phase II	NCT00778700
	Tofacitinib	JAK1/JAK3	Topical	Phase II	NCT01831466
			Topical	Phase II	NCT01246583
			Topical	Phase II	NCT00678561
			Topical	Phase I	NCT02193815
	PF-06700841	JAK1/TYK2	Topical	Phase II	NCT03850483
Vitiligo	Ruxolitinib	JAK1/JAK2	Topical	Phase III	NCT04057573
			Topical	Phase III	NCT04052425
			Topical	Phase III	NCT04530344
			Topical	Phase II	NCT02809976
			Topical	Phase II	NCT03099304

GVHD, graft-versus-host disease; JAK, Janus kinase; JAKinibs, JAK-inhibitors.